Owens & Minor Inc. (OMI)
NYSE: OMI
· Real-Time Price · USD
5.54
0.14 (2.59%)
At close: Sep 23, 2025, 11:02 AM
Owens & Minor Revenue Breakdown
| Period Ending | Jun 30, 2025 |
|---|---|
| Diabetes Product Revenue | 191.06M |
| Diabetes Product Revenue Growth | n/a |
| Product and Service, Other Revenue | 72.3M |
| Product and Service, Other Revenue Growth | n/a |
| Urology Revenue | 28.7M |
| Urology Revenue Growth | n/a |
| Wound Care Revenue | 46.82M |
| Wound Care Revenue Growth | n/a |
Revenue by Geography
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Us Revenue | 51.33M | 59.22M | 59.66M | 62M | 62.07M | 67.9M | 72.79M | 64.69M | 69.91M | 74.45M | 86.61M | 123.44M | 144.93M | 117.04M | 121.38M | 152.79M | 143.78M | 103.57M | 86.85M | 70.1M | 89.24M | -230.3M | 198.73M | 213.43M | 157.47M | -23.41M | 264.68M | 209.54M | 119.94M |
| Non-Us Revenue Growth | -13.32% | -0.73% | -3.77% | -0.12% | -8.58% | -6.72% | +12.52% | -7.47% | -6.10% | -14.04% | -29.84% | -14.83% | +23.84% | -3.58% | -20.56% | +6.27% | +38.82% | +19.24% | +23.89% | -21.44% | -138.75% | -215.88% | -6.89% | +35.53% | -772.77% | -108.84% | +26.31% | +74.70% | n/a |
| United States Revenue | 2.58B | 2.64B | 2.66B | 2.61B | 2.55B | 2.59B | 2.52B | 2.5B | 2.45B | 2.48B | 2.41B | 2.38B | 2.26B | 2.35B | 2.38B | 2.34B | 2.18B | 2.26B | 2.1B | 1.74B | n/a | 2.1B | n/a | n/a | 2.3B | 2.57B | 2.2B | 2.25B | 2.25B |
| United States Revenue Growth | -2.13% | -0.92% | +2.01% | +2.29% | -1.45% | +2.75% | +0.82% | +1.86% | -0.96% | +2.73% | +1.44% | +5.06% | -3.75% | -1.29% | +1.89% | +7.05% | -3.34% | +7.48% | +20.92% | n/a | n/a | n/a | n/a | n/a | -10.23% | +16.64% | -2.16% | -0.17% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 267.85M | 462.35M | 493.07M | 469.8M | 469.31M | 423.82M | 457.23M | 452.58M | 455.03M | 448.72M | 455.86M | 445.26M | 452.81M | 279.74M | 267.62M | 262.46M | 294.1M | 292.7M | 282.85M | 262.54M | 241.73M | 254.05M | 255.42M | 332.37M | 345.89M | 338.7M | 343.6M | 325.01M | 308.77M | 284.36M | 281.63M | 261.05M | 236.62M | 237.69M | 243.48M | 241.31M | 242.91M | 242.72M | 236.43M | 231.85M | 231.5M | 233.82M |
| Selling, General, and Administrative Revenue Growth | -42.07% | -6.23% | +4.95% | +0.10% | +10.73% | -7.31% | +1.03% | -0.54% | +1.41% | -1.56% | +2.38% | -1.67% | +61.87% | +4.53% | +1.97% | -10.76% | +0.48% | +3.48% | +7.74% | +8.61% | -4.85% | -0.54% | -23.15% | -3.91% | +2.12% | -1.43% | +5.72% | +5.26% | +8.59% | +0.97% | +7.88% | +10.32% | -0.45% | -2.38% | +0.90% | -0.66% | +0.08% | +2.66% | +1.98% | +0.15% | -1.00% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | 13.2M | n/a | n/a | n/a | 11.8M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |